A shift in the temporary telehealth items are forcing doctors to consider opting for more video, rather than telephone consults with their patients. For the full article please visit:https://medicalrepublic.com.au/mbs-changes-aim-to-increase-video-consults/46331
Proponents for digital transformation say remote consults could assist patients and doctors, but only if the right settings are in place. Telehealth advocates are calling for greater funding certainty for digital services and infrastructure that they say could improve healthcare across the country. Following the Federal Government’s commitment to extend Medicare-funded telehealth another six months to December, Telehealth...
ASX listed digital health company ResApp has signed a memorandum of understanding with health products manufacturer RB, formerly known as Reckitt Benckiser, to develop a smartphone app for consumers that uses ResApp’s cough-based algorithms to identify different respiratory conditions. For the full article please visit:
Respiri’s agreement with the Pharmacy Guild of Australia will build awareness and knowledge of its wheeze respiratory evaluation device and technology. Respiri has already secured telehealth partnerships with Phenix Health and Practice Innovators to grow use and awareness of the technology throughout Australia. For the full article please visit: https://smallcaps.com.au/respiri-wheezo-market-agreement-pharmacy-guild-of-australia/
The average GP consultation take about six minutes. That figure is very significant in the context of the two-year, non-exclusive commercial software licensing agreement Resapp Health [ASX:RAP] has just signed with Phenix Health Pty Ltd. Phenix Health Pty Ltd is an integrative medical tech company founded in 2015 as a spin-off from its Australia-wide after-hours...
In March, ResApp announced to have completed the initial integration of ResAppDx-EU into Coviu’s telehealth platform and that ResApp and Coviu had agreed upon a per test fee (range of $ 5-10 per test) for the use of ResAppDx-EU. Meanwhile, ResApp also executed Joint Development Agreement with Phenix Health for integration of ResAppDx-EU into Phenix’s Australian telehealth...
Wheezo asthma diagnostic and monitoring technology Respiri has developed its wheezo device and eHealth software as a service technology to support the management of respiratory health. Machine learning is employed to detect wheeze via the wheezo device and app. Wheeze is a typical asthma symptom and is common in other respiratory disorders. The technology is...
Medicare billing app vendor Synapse Medical Services has partnered with virtual GP clinic Phenix Health to provide a mobile telehealth and billing solution for the COVID-19 pandemic. Doctors can complete a telehealth consult on the Phenix platform, bill it, and receive a response from Medicare instantly to their phone along with overnight payment. For the...
* RESPIRI LTD – ANNOUNCES SIGNING OF A JOINT DEVELOPMENT AGREEMENT (JDA) WITH PHENIX HEALTH PTY LTD * RESPIRI-UNDER DEAL,WHEEZO EHEALTH SAAS MONITORING PLATFORM INTEGRATED INTO PHENIX PROPRIETARY TELEHEALTH PLATFORM, PATIENT DASHBOARDS & ASTHMA PLANS https://au.investing.com/news/stock-market-news/briefrespiri-announces-signing-of-a-joint-development-agreement-with-phenix-health-2092571
ASX-listed ResApp Health will partner with Brisbase-headquartered telehealth provider Phenix Health to integrate ResApp’s acute respiratory diagnostic test into Phenix’s telehealth app. ResApp has recently completed a similar integration of ResAppDx-EU into Coviu’s telehealth platform and is expecting to have it available for use in a few months. The company is also about to launch a consumer-focused...
OUR AFFILIATES
Phenix Health delivers online health services 24/7 provided by Australian doctors and healthcare professionals.